Maravai LifeSciences Holdings, (MRVI) Stock Price & How to Invest
Last updated November 2026
Short answer
Maravai LifeSciences (MRVI) sells the raw materials and safety-testing kits that drug makers use to build mRNA medicines and biologics. After the COVID boom collapsed, the stock fell to roughly $2 to $4 in 2025. It traded near $7.03 on November 20, 2026, about double a year earlier, because the business has returned to positive adjusted EBITDA and raised its 2026 guidance again in November. No takeover is involved. At about 9x sales, the price already assumes that steady non-COVID growth continues.
MRVI stock price
As of 2026-11-20, Maravai LifeSciences Holdings, (MRVI) last closed at $6.98, up 86.1% over the past year. Over the past 52 weeks it has traded between $2.83 and $9.00.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Maravai LifeSciences Holdings,'s investor relations page. Walnut is informational, not investment advice.
MRVI key stats
At $6.98 on November 20, 2026, Maravai LifeSciences Holdings, (MRVI) has a market cap of $1.8B.
- Market cap
- $1.8B
- Price to book
- 5.3
- Beta
- 0.63
Market cap, P/E and yield are measured at the $6.98 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Maravai LifeSciences Holdings, (MRVI)?
The last two weeks for Maravai LifeSciences Holdings,, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- MRVI closed at $6.98 on November 20, 2026, down 7.4% over the past five trading days (from $7.54).
- On November 12, 2026, Keybanc started coverage at Overweight, target $11.00.
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Maravai LifeSciences Holdings, (MRVI) do?
Maravai LifeSciences is a San Diego life sciences tools company that GTCR controls. It runs two businesses. The larger is TriLink BioTechnologies, which makes the nucleic acid building blocks behind mRNA medicines: CleanCap capping reagents, modified nucleotides, enzymes, DNA templates and custom mRNA, sold for research and in GMP grade for clinical and commercial production. The second is Cygnus Technologies. It sells host cell protein (HCP) detection kits, ELISA assays and related services, which biologics manufacturers use to show regulators that impurities have been removed from their drugs. In 2021 and 2022, CleanCap orders tied to COVID vaccines pushed revenue close to $900M. When those orders went away, revenue fell to about $186M in 2025, along with large losses, goodwill writedowns and layoffs.
The 2026 numbers show a turnaround. First-half revenue was ~$117.3M, up 24% year over year. That figure includes ~$14.3M of one-off commercial COVID CleanCap orders booked in Q1. Excluding them, TriLink base revenue grew ~13%. Q2 revenue was ~$51.4M, up 8.5%: TriLink ~$34.7M (+11.5%) and Cygnus ~$16.8M (+2.8%). Q2 adjusted EBITDA was ~$8.7M, compared with a loss of ~$10.4M a year earlier. Gross margin recovered to about 40% in the quarter and 46% for the half. At that point management kept its 2026 revenue guidance at $205M to $215M and raised adjusted EBITDA guidance to $33M to $35M. Q3 2026, reported November 4, kept the trend going: revenue was ~$45.9M, up 10.1% from ~$41.6M, with TriLink at ~$28.4M (+11.8%) and Cygnus at ~$17.5M (+7.5%), its sixth straight quarter of growth. Adjusted EBITDA was ~$5.8M against a ~$10.8M loss a year earlier, the net loss narrowed to ~$24.0M from ~$45.1M, and the adjusted loss of $0.03 per share beat the ~$0.06 consensus. Management raised 2026 guidance again, to revenue of $212M to $216M and adjusted EBITDA of $40M to $42M. CEO Bernd Brust is also opening a GMP enzyme plant and expanding the ModTail product line.
As of November 20, 2026, MRVI trades around $7.03, roughly double its level of a year ago (up about 107% year to date) but down about 22% over three months from a 52-week high near $9.42. It trends because of that rebound, a run of sharp daily moves (including about +9% on October 27), new Buy coverage from TD Cowen, the November guidance raise and a KeyBanc upgrade to Overweight with an $11 target on November 12. No takeover offer or merger agreement has been announced. The 2025 securities class action was dismissed with prejudice in early 2026. What has changed is that Maravai is now valued as a profitable mRNA picks-and-shovels supplier instead of a shrinking COVID business. That higher valuation, about 9x trailing sales, depends on the recovery continuing.
What's driving Maravai LifeSciences Holdings, (MRVI)?
1. TriLink base mRNA demand outside COVID
TriLink is about two thirds of revenue and drives the story. Excluding COVID, its base revenue grew ~13.4% in the first half of 2026, from Discovery mRNA research reagents and GMP consumables used in clinical trials. Q2 TriLink revenue was ~$34.7M, up 11.5%, and Q3 TriLink revenue was ~$28.4M, up 11.8%, with mRNA revenue up 28% year over year and four Discovery mRNA customers moving to clinical-stage GMP material in the quarter. The bullish argument is that each mRNA program for cancer vaccines, rare diseases, in vivo cell therapy or gene editing that moves from discovery to the clinic needs more and higher-grade material, and much of it is locked into CleanCap. TriLink also received new China patents for CleanCap in July and September 2026. If base growth holds in the low teens, TriLink could grow even without another pandemic-scale order.
2. Margin repair and operating leverage
The bigger change is cost structure, more than revenue. After the 2025 Corporate Realignment Plan, Q2 2026 SG&A fell to ~$32.1M from ~$38.7M, and first-half operating expenses fell about 45%. Gross margin rose from about 16% in Q2 2025 to roughly 40% in Q2 2026. Adjusted EBITDA swung from a ~$10.4M loss to a ~$8.7M profit. Q3 adjusted EBITDA was ~$5.8M against a ~$10.8M loss a year earlier, and Q3 gross margin was about 35%. In November management raised full-year adjusted EBITDA guidance for a second time, to $40M to $42M on revenue of $212M to $216M, an implied margin of about 19%. Tools businesses carry high fixed costs, so each extra dollar of revenue should add more profit from here. That leverage is what bulls are paying for.
3. New products: ModTail, enzymes and an end-to-end mRNA kit
Maravai wants to supply every input of mRNA manufacturing, not only the cap. ModTail, a modified poly(A) tail technology, had more than 125 active customers about a year after launch. In June 2026 TriLink opened a GMP enzyme manufacturing facility, which rounds out its in vitro transcription (IVT) raw materials, and it already sells an mRNA synthesis kit that includes CleanCap. The Officinae Bio DNA and RNA business, acquired in early 2025, adds synthetic DNA template capability. The goal is to be a single supplier from early research through commercial production. Customers who validate a supplier's materials in a regulatory filing rarely switch, so programs won at the research stage tend to stay as they scale.
4. Cygnus biologics safety testing as the steady base
Cygnus is smaller, at ~$16.8M of Q2 revenue (up 2.8%) and ~$17.5M in Q3 (up 7.5%, a sixth consecutive quarter of growth), but historically it is very profitable and much less volatile than TriLink. Its HCP ELISA kits, antibody development and HCP coverage analysis services are built into the release testing of many biologics, and regulators expect process-specific impurity testing to continue. Growth is closer to single digits than double digits. The value is stability: Cygnus revenue follows the volume of approved and late-stage biologics, which moves slowly. A steady 3% to 6% grower with strong margins gives Maravai a floor that TriLink's lumpier mRNA business does not.
What are the risks to Maravai LifeSciences Holdings, (MRVI)?
Valuation is the first risk. At about $7.03, MRVI trades near 9x trailing sales of ~$213M and more than 40x the midpoint of the raised 2026 adjusted EBITDA guidance, which leaves little room for a weak quarter; consensus also has 2027 revenue only about 5% above 2026 guidance. Revenue is concentrated: Pfizer accounted for ~12% of first-half revenue, and a single vaccine customer accounted for ~18% of receivables at mid-year. Management has said it does not expect more high-volume COVID orders in 2026, and Q2 COVID CleanCap revenue was zero, so the year-over-year comparison gets harder. Cash fell from ~$217M at year-end 2025 to ~$70M at June 30, 2026, mostly because the company used cash to repay debt, leaving a $150M term loan due 2032; Yahoo Finance shows ~$73M of cash and ~$226M of total debt after Q3. Wider mRNA sentiment, including US policy pullbacks on mRNA vaccine funding, can hit research budgets. Competition from Thermo Fisher, Danaher's Aldevron and low-cost Chinese suppliers could pressure CleanCap pricing as patents age. GTCR controls the majority of voting power, so outside shareholders have limited influence, and future GTCR sales could add supply. The stock moves sharply in both directions: it fell about 22% over the three months to November 20, 2026 even as guidance rose.
What is the Maravai LifeSciences Holdings, (MRVI) forecast?
7 analysts publish price targets on MRVI, averaging $9.64 as of November 2026, or +38.1% against the $6.98 share price on November 20, 2026. The published targets run from $8.00 to $12.00, a moderate spread, and the ratings split 6 buy, 3 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full MRVI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is MRVI a buy or a sell?
We give no verdict on Maravai LifeSciences Holdings,. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. TriLink base mRNA demand outside COVID. TriLink is about two thirds of revenue and drives the story. The most optimistic published target, $12.00, assumes this works close to its best case.
The case against. Valuation is the first risk. The most pessimistic target, $8.00, is roughly what MRVI is worth if this bites instead.
Read the full bull and bear case on MRVI, including what would have to change to break either one. Walnut is not an investment adviser.
How is Maravai LifeSciences Holdings, (MRVI) valued?
Market cap, P/E and dividend yield at today's price are in the MRVI key stats above. The business figures below come from Maravai LifeSciences Holdings,'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$213M (Q3 2026 +10% YoY)
- 2026 revenue guidance: ~$212M to $216M (raised from $205M to $215M)
- 2026 adj. EBITDA guidance: ~$40M to $42M (raised from $33M to $35M)
- Q3 2026 adj. EPS: -$0.03 vs ~-$0.06 consensus
- Net loss (TTM): ~$66M
- EV / TTM sales: ~9x
- Cash vs. total debt (Sep 30): ~$73M vs ~$226M
As of November 2026: The market cap above counts all ~260M Class A shares and exchangeable Class B units at about $7.03, which matches the figure Yahoo Finance shows. Adding ~$226M of debt and subtracting ~$73M of cash gives an enterprise value near $2.0B, about 9x trailing sales and roughly 48x the midpoint of the raised adjusted EBITDA guidance, still well above many slower-growth life sciences tools peers. GAAP results are still loss-making (a ~$24.0M Q3 net loss), so investors are valuing adjusted EBITDA and its direction. Seven analysts tracked by Yahoo Finance carry a mean target near $9.64.
Who competes with Maravai LifeSciences Holdings, (MRVI)?
Large-cap mRNA and nucleic acid suppliers
Thermo Fisher Scientific and Danaher (through Aldevron and Cytiva) sell competing capping reagents, nucleotides, enzymes and plasmid DNA, and they can bundle these with instruments and contract manufacturing. They have far more scale and sales reach than TriLink. Maravai's defense is the CleanCap patents and its deep relationships with mRNA developers.
Specialist and lower-cost reagent makers
New England Biolabs, Hongene Biotech and a growing group of Chinese nucleotide and enzyme suppliers compete on price, especially for research-grade material. Merck KGaA (MilliporeSigma) also supplies mRNA raw materials and services. These companies limit TriLink's pricing power wherever a customer's process is not yet locked to a validated supplier.
Biologics impurity and safety testing
In host cell protein and process-impurity testing, Cygnus competes with assay and service offerings from Thermo Fisher, Bio-Techne, Charles River Laboratories and mass-spectrometry contract labs. Cygnus is known for its HCP kits and coverage analysis, but large CROs and in-house analytical teams are alternatives for big biopharma.
What stocks are similar to Maravai LifeSciences Holdings, (MRVI)?
Other names that sit close to MRVI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Maravai LifeSciences Holdings, (MRVI)
There are three common ways to get MRVI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MRVI sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where MRVI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Maravai LifeSciences Holdings, (MRVI)
MRVI is a recovering mRNA and bioprocessing tools supplier. Margins are back, the Q3 2026 report raised full-year guidance and the debt is smaller, but at roughly 9x sales the price assumes the growth continues, cash is thinner than before, and the shares have fallen about 22% over three months even after the beat.
More on Maravai LifeSciences Holdings, (MRVI)
Whether MRVI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MRVI a buy or a sell?, and where the stock could go from here in the MRVI stock forecast.
For income investors, whether MRVI pays a dividend and how the payout looks is covered in does MRVI pay a dividend? And to weigh MRVI against a peer, read the full side-by-side comparisons: MRVI vs TMO and MRVI vs DHR.
Wondering how MRVI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Maravai LifeSciences Holdings,
Ask Walnut's AI anything about MRVI and see how it fits what you own.
FAQ
What does Maravai LifeSciences do?
+
Maravai supplies the materials and tests used to develop and manufacture biologic drugs. Its TriLink BioTechnologies unit makes the components of mRNA medicines: CleanCap capping reagents, modified nucleotides, enzymes, DNA templates and custom mRNA, in both research and GMP grades. Its Cygnus Technologies unit sells host cell protein detection kits, ELISA assays and analytical services that help manufacturers show regulators that impurities have been removed from therapeutic proteins. Maravai does not develop its own drugs. It sells to pharmaceutical and biotech companies, academic labs and contract manufacturers. In the first half of 2026, TriLink produced roughly two thirds of revenue and Cygnus the rest. GTCR, the private equity firm, still controls the majority of voting power.
Why is MRVI stock trending in October 2026?
+
MRVI roughly doubled over the twelve months to late October 2026, reaching around $8.50, with several sharp single-day gains, including about +8% on October 20 and about +9% on October 27. TD Cowen started coverage with a Buy rating and a $9 target in early October. Third-quarter results on November 4 beat estimates and raised 2026 guidance, and KeyBanc upgraded the stock to Overweight with an $11 target on November 12, though the shares eased to about $7.03 by November 20. The move follows evidence that the business has stabilized: adjusted EBITDA turned positive and gross margin recovered toward the 40% range. No takeover offer, merger agreement or other single event explains the rally. It reflects the market revaluing the company as a recovery.
Is Maravai being acquired?
+
As of November 2026, no takeover offer, definitive merger agreement or strategic review has been publicly announced. The higher share price does not follow a deal price. It reflects the company's own results and analyst coverage. That point matters because a stock pinned to a cash offer behaves very differently from one priced on fundamentals. Maravai has been the acquirer instead: it bought Officinae Bio's DNA and RNA business and assets from Molecular Assemblies in early 2025. GTCR controls the majority of the vote, so any future sale would need its support. Speculation about a buyer occasionally appears, but none is confirmed. Check the company's SEC filings for any change.
How did Maravai do in its most recent quarter?
+
In Q3 2026, reported November 4, revenue was ~$45.9M, up 10.1% year over year. TriLink grew 11.8% to ~$28.4M on Discovery mRNA and GMP consumables, and Cygnus grew 7.5% to ~$17.5M on HCP and ELISA kits. Net loss narrowed to ~$24.0M from ~$45.1M, adjusted EBITDA was ~$5.8M against a ~$10.8M loss a year earlier, and the adjusted loss of $0.03 per share beat the ~$0.06 consensus. Management raised 2026 guidance to $212M to $216M of revenue and $40M to $42M of adjusted EBITDA. In the prior quarter, Q2, revenue was ~$51.4M and adjusted EBITDA ~$8.7M. Q1 had included ~$14.3M of one-time commercial COVID CleanCap orders.
How much does COVID still matter to Maravai?
+
Much less than it once did, but it still matters at the margin. During the pandemic, CleanCap orders for COVID vaccines made up most of Maravai's revenue, and total revenue approached $900M in 2021 and 2022. In the first half of 2026, high-volume commercial COVID CleanCap orders contributed ~$14.3M, all in Q1, and nothing in Q2. Management has said it does not expect more high-volume COVID orders this year. That means first-half growth of 24% overstates the underlying trend. The more useful measure is TriLink base revenue excluding COVID, which grew about 13% in the first half; Q3 TriLink revenue grew 11.8% with no separate COVID figure reported. COVID orders now act as an occasional bonus, not a foundation.
What happened with the Maravai securities class action?
+
In early 2025 shareholders filed a securities class action (Nelson v. Maravai LifeSciences Holdings, S.D. Cal.) after the company delayed its Q4 2024 report and disclosed problems with revenue recognition controls and goodwill. On January 15, 2026, the court granted the defendants' motion to dismiss the amended complaint. The lead plaintiff then chose not to amend or appeal, and the case was dismissed with prejudice in February 2026. A related shareholder derivative suit was dropped afterward. Public reports show no settlement payment. The case is therefore closed, though the underlying control weaknesses were part of the company's difficult 2025.
How is MRVI valued compared with other tools stocks?
+
At about $7.03 and ~260M combined Class A and Class B shares, Maravai's equity value is around $1.8B. Adding ~$226M of total debt and subtracting ~$73M of cash gives an enterprise value of roughly $2.0B. That is about 9x trailing revenue of ~$213M and about 48x the midpoint of the raised 2026 adjusted EBITDA guidance of $40M to $42M. Large diversified tools companies such as Thermo Fisher and Danaher have typically traded at lower sales multiples with much higher margins. The premium reflects expectations that Maravai's margins keep expanding and that mRNA demand grows. If growth slows back to single digits, that multiple has more room to fall than a mature peer's.
How can someone get exposure to Maravai or mRNA tools?
+
MRVI trades on Nasdaq and can be bought through most US brokerages, including fractional shares at some brokers. Its Class A shares are the listed security. For broader exposure, some investors look at a group of bioprocessing and life sciences tools names (for example Maravai alongside Thermo Fisher, Danaher, Repligen and Bio-Techne) or healthcare and biotech ETFs, which hold several suppliers instead of one. A basket built around a theme such as mRNA medicines or bioprocessing can be tracked against target weights in Walnut and compared with the S&P 500. Walnut is not an investment adviser. Position size, time horizon and tolerance for a volatile small-cap are decisions for each investor, ideally with a licensed professional.
How has MRVI stock performed in 2026?
+
As of November 20, 2026 MRVI closed near $7.03, up about 107% year to date and about 106% over one year, within a 52-week range of roughly $2.80 to $9.42. The shares fell about 22% over the latest three months and about 4% over one month, so much of the gain came earlier in the year. Seven analysts tracked by Yahoo Finance carry a mean target near $9.64.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Maravai LifeSciences Holdings,'s investor relations page or your broker before making investment decisions.